secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcutis Biotherapeutics, Inc. (ARQT)
CIK:        0001787306
Form:       8-K
Filed at:   2024-08-14T23:59:59+00:00
Accession:  0001787306-24-000122
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcutis Q2 product revenue $30.9M, up 547% YoY; net loss narrows to $52.3M
--------------------------------------------------------------------------

- ZORYVE franchise net product revenue $30.9M ($17.3M cream, $13.6M foam); 43% sequential growth.
- Net loss $52.3M ($0.42/share) vs $71.0M loss in Q2 2023; cash $363.1M.
- Entered co-promotion with Kowa Pharmaceuticals for primary care and pediatric promotion of ZORYVE.
- Submitted sNDA for ZORYVE foam for scalp/body psoriasis; FDA approved cream 0.15% for atopic dermatitis.
- Amended $200M term loan: rate reduced 150bps, maturity extended to June 2029, $100M prepay/re-draw option.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787306/000178730624000122/0001787306-24-000122-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787306/000178730624000122/arqt-20240814.htm
  HTML page:      https://secwatch.observer/filing/0001787306-24-000122

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer